Oral erosive lichen planus treated with efalizumab

Archives of Dermatology

Volumn 142, Issue 6, 2006, Pages 680-682

  Cheng, Amy ^a   Mann, Caroline ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; EFALIZUMAB; EOSIN; HEMATOXYLIN; HYDROGEN PEROXIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NYSTATIN; PREDNISONE; STEROID; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; BLOOD SAMPLING; BODY REGIONS; BRUCH MEMBRANE; CASE REPORT; DOSE RESPONSE; ERYTHEMA; FEMALE; GINGIVITIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LABORATORY TEST; LICHEN PLANUS; LICHENOID ERUPTION; MOUTH PAIN; MUCOUS MEMBRANE PEMPHIGOID; OINTMENT; ORAL ERUPTION; ORAL MUCOSAL DISEASE; PAPULE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN EXAMINATION; STAINING; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LICHEN PLANUS, ORAL; MIDDLE AGED; PREDNISONE; TACROLIMUS;

EID: 33745242379     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.6.680     Document Type: Article

References (26)

1. Axell T, Rundquist L. Oral lichen planus: a demographic study. Community Dent Oral Epidemiol. 1987;15:52-56.
2. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46: 207-214.
3. Epstein JB, Wan LS, Gorsky M, Zhang L. Oral lichen planus: progress in understanding its malignant potential and the implications for clinical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;96:32-37.
4. Setterfield JF, Black MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol. 2000;25:176-182.
5. Scully C, Eisen D, Carrozzo M. Management of oral lichen planus. Am J Clin Dermatol. 2000;1:287-306.
6. Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol. 2000;136:1442-1443.
7. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis. 1999; 5:196-205.
8. Edwards PC, Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc. 2002;68:494-499.
9. Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin. 2003;21:79-89.
10. Eisen D, Eliis CN, Duell EA, Griffiths C, Voorhees J. Effect of topical cyclosporine rinse on oral lichen planus. N Engl J Med. 1990;323:290-294.
11. Eisen D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol. 1993;28:609-612.
12. Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin: a double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol. 1991;24:434-437.
13. Lozada-Nur F, Miranda C. Oral lichen planus: topical and systemic therapy. Semin Cutan Med Surg. 1997;16:295-300.
14. Morrison L, Kratochvil J III, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002;47:617-620.
15. Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol. 1999;135:1420-1421.
16. Stefanidou MP, Ioannidou DJ, Panayiotides JG, Tosca AD. Low molecular weight heparin; a novel alternative therapeutic approach for lichen planus. Br J Dermatol. 1999;141:1040-1045.
17. Yamamoto T, Osaki T, Yoneda K, Ueta E. Cytokine production by keratinocytes and mononuclear infiltrates in oral lichen planus. J Oral Pathol Med. 1994;23:309-315.
18. Yamamoto T, Osaki T. Characteristic cytokines generated by keratinocytes and mononuclear infiltrates in oral lichen planus. J Invest Dermatol. 1995;104:784-788.
19. Walton LJ, Thornhill M, Farthing PM. VCAM-1 and ICAM-1 are expressed by Langerhans cells, macrophages and endothelial cells in oral lichen planus. J Oral Pathol Med. 1994;23:262-268.
20. Eversole LR. Adhesion molecules and oral mucosal diseases. Oral Dis. 1996;2: 185-187.
21. Eversole LR, Dam J, Ficarra G, Hwang CY. Leukocyte adhesion molecules in oral lichen planus: a T cell-mediated immunopathologic process. Oral Microbiol Immunol. 1994;9:376-383.
22. Mollaoglu N. Oral lichen planus: a review. Br J Oral Maxillofac Surg. 1997;38: 370-377.
23. Chan ES, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 2002;2:CD001168.
24. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003;49:S98-S104.
25. Yamamoto T, Nakane T, Osaki T. The mechanism of mononuclear cell infiltration in oral lichen planus: the role of cytokines released from keratinocytes. J Clin Immunol. 2000;20:294-305.
26. Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004;208:297-306.